Business Description
ISIN : US5898891040
Share Class Description:
MMSI: Ordinary SharesTotal Employee Number:
7,500Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.55 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | 2.27 | |||||
Interest Coverage | 6.33 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 4.25 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.9 | |||||
3-Year EBITDA Growth Rate | 20.5 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | 45.3 | |||||
3-Year Book Growth Rate | 10.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.84 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.58 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.43 | |||||
9-Day RSI | 39.65 | |||||
14-Day RSI | 49.68 | |||||
3-1 Month Momentum % | 34.85 | |||||
6-1 Month Momentum % | 22.54 | |||||
12-1 Month Momentum % | -3.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.2 | |||||
Quick Ratio | 2.79 | |||||
Cash Ratio | 1.69 | |||||
Days Inventory | 156.61 | |||||
Days Sales Outstanding | 48.5 | |||||
Days Payable | 30.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -0.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 49.51 | |||||
Operating Margin % | 12.74 | |||||
Net Margin % | 9.22 | |||||
EBITDA Margin % | 22.94 | |||||
FCF Margin % | 12.65 | |||||
OCF Margin % | 17.95 | |||||
ROE % | 9.2 | |||||
ROA % | 5.4 | |||||
ROIC % | 7.35 | |||||
3-Year ROIIC % | 8.03 | |||||
ROC (Joel Greenblatt) % | 25.85 | |||||
ROCE % | 9.19 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 35.9 | |||||
Forward PE Ratio | 18.8 | |||||
PE Ratio without NRI | 24.46 | |||||
Shiller PE Ratio | 73.01 | |||||
Price-to-Owner-Earnings | 26.8 | |||||
PEG Ratio | 1.03 | |||||
PS Ratio | 3.29 | |||||
PB Ratio | 3.09 | |||||
Price-to-Tangible-Book | 9.83 | |||||
Price-to-Free-Cash-Flow | 26.08 | |||||
Price-to-Operating-Cash-Flow | 18.35 | |||||
EV-to-EBIT | 24.57 | |||||
EV-to-Forward-EBIT | 19.09 | |||||
EV-to-EBITDA | 15.35 | |||||
EV-to-Forward-EBITDA | 16.6 | |||||
EV-to-Revenue | 3.52 | |||||
EV-to-Forward-Revenue | 3.21 | |||||
EV-to-FCF | 27.83 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Projected-FCF | 1.53 | |||||
Price-to-DCF (Earnings Based) | 1.15 | |||||
Price-to-DCF (FCF Based) | 1.32 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
Price-to-Graham-Number | 3.27 | |||||
Earnings Yield (Greenblatt) % | 4.07 | |||||
FCF Yield % | 3.85 | |||||
Forward Rate of Return (Yacktman) % | 22.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MMSI
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Merit Medical Systems Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,578.813 | ||
| EPS (TTM) ($) | 2.42 | ||
| Beta | 0.2595 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 33.15 | ||
| 14-Day RSI | 49.68 | ||
| 14-Day ATR ($) | 2.175765 | ||
| 20-Day SMA ($) | 90.228 | ||
| 12-1 Month Momentum % | -3.56 | ||
| 52-Week Range ($) | 59.74 - 94.7482 | ||
| Shares Outstanding (Mil) | 59.71 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merit Medical Systems Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merit Medical Systems Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 169 days | ||
| Annual report for 2026 | 2027-02-24 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 17:00 | In 52 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 51 days | ||
| The Sidoti Small Cap Conference | 2026-09-23 | In 14 days | ||
| Guidance call for 2026 | 2026-09-15 08:30 | In 7 days | ||
| Guidance call for 2026 | 2026-09-10 08:45 | In 2 days | ||
| The Bank of America SMID Cap Conference | 2026-08-12 09:00 | 91.11 (+1.30%) | ||
| The Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 11:00 | 89.75 (+0.80%) |
Merit Medical Systems Inc Frequently Asked Questions
Guru Commentaries on NAS:MMSI
We maintain a position in Merit Medical Systems, as we believe the company may continue to benefit from durable demand, expanding margins, and secular growth tied to digital and regulatory complexity in their end markets over the long term.
Merit Medical Systems, Inc. (MMSI) faced challenges due to concerns about its sales in China and the potential impact of tariffs. The company reported solid 1Q results, but the revised EPS guidance down for 2025 primarily due to tariffs in China has raised concerns. Despite these challenges, the company expects to offset about 45% of tariff headwinds through operational efficiencies, but the overall sentiment remains cautious given the external pressures.
Merit Medical Systems, Inc. (MMSI) delivered strong quarterly results, exceeding expectations for both sales and earnings growth. The company's vertically integrated business model continued to provide manufacturing stability and competitive advantage in both cardiovascular and endoscopy segments. Its OEM segment resonated with customers’ persistent supply chain challenges in the industry. Gross and operating margins showed consistent improvement, positioning MMSI well to achieve its long-term targets. Recent product launches and strategic acquisitions enhance MMSI's position in higher-growth therapeutic markets.
